(Q37706610)

22 August 2017

1 reference

title

MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk (English)

1 reference

22 August 2017

1 reference

3

Filippo Ansaldi

1 reference

22 August 2017

2

Giancarlo Icardi

1 reference

22 August 2017

1

Paolo Durando

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 April 2010

1 reference

Expert Opinion on Biological Therapy

22 August 2017

published in

1 reference

22 August 2017

volume

10

1 reference

22 August 2017

issue

4

1 reference

22 August 2017

page(s)

639-651

1 reference

Influenza deaths in Leicestershire during the 1989-90 epidemic: implications for prevention

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Impact of influenza on mortality in relation to age and underlying disease, 1967-1989.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Mortality associated with influenza and respiratory syncytial virus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Epidemiology and unique aspects of aging and infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

The burden of influenza illness in children with asthma and other chronic medical conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Influenza and the rates of hospitalization for respiratory disease among infants and young children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

The annual impact of seasonal influenza in the US: Measuring disease burden and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Socioeconomic impact of influenza on healthy children and their families

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Influenza and respiratory syncytial virus in infants and children: relationship with attendance at a paediatric emergency unit and characteristics of the circulating strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

The underrecognized burden of influenza in young children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Immunogenicity and protective efficacy of influenza vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Influenza control in the 21st century: Optimizing protection of older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Influenza vaccination: policy versus evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

The immunogenicity of influenza virus vaccine in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Influenza vaccine--outmaneuvering antigenic shift and drift

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Influenza vaccine: the challenge of antigenic drift.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

New A/H3N2 influenza variant: a small genetic evolution but a heavy burden on the Italian population during the 2004-2005 season.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Real-time monitoring of the influenza vaccine field effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Preparing for pandemic vaccination: an international policy agenda for vaccine development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Safety of High Doses of Influenza Vaccine and Effect on Antibody Responses in Elderly Persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

An open-label comparison of the immunogenicity and tolerability of intranasal and intramuscular formulations of virosomal influenza vaccine in healthy adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Live attenuated versus inactivated influenza vaccine in infants and young children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

The virosome concept for influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Increased immunogenicity of the MF59-adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Comparison of the reactogenicity and immunogenicity of a split and a subunit-adjuvanted influenza vaccine in elderly subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Response of influenza vaccines against heterovariant influenza virus strains in adults with chronic diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Molecular and cellular signatures of human vaccine adjuvants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

21 January 2018

Safety of MF59 adjuvant

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Neutralizing and hemagglutination-inhibiting activities of antibodies elicited by the 2004-2005 influenza vaccine against drifted viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Antibodies to squalene in Gulf War syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

The endogenous adjuvant squalene can induce a chronic T-cell-mediated arthritis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

The arthritogenic adjuvant squalene does not accumulate in joints, but gives rise to pathogenic cells in both draining and non-draining lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Induction of lupus autoantibodies by adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Failure of influenza vaccination in the aged

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

Influenza in the elderly: report of an outbreak and a review of vaccine effectiveness reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712591003724662

10.1517/14712591003724662

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference